Allogeneic Transplantation
Leukemia Trials (AML & ALL)
COMIRB: 22-0054
Phase I Safety and Tolerability Trial of CD19 Directed CAR T Cells in Adult Patients with B-Cell Acute Lymphoblastic Leukemia (B-ALL) with Minimal Residual Disease (MRD) Positivity at First Complete Remission
PI: Mat Angelos
Eligibility: Ages ≥ 18; B-cell ALL in first complete morphologic remission; MRD positive; ECOG of ≤2
COMIRB: 22-1050
Phase I study of SNDX-5613 in Patients with Relapsed/refractory Leukemias Including those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin1 (NPM1) Mutation
PI: Christine McMahon
Relapsed/refractory AML; ECOG of less than or equal to 2; adequate organ function
COMIRB: 23-0061
KO-MEN-007: Phase 1 study of venetoclax/azacitidine or venetoclax + ziftomenib (KO-539) or standard induction cytarabine/daunorubicin (7+3) + ziftomenib for AML)
Principal Investigator: Christine McMahon
Eligibility criteria described at link below.
COMIRB: 23-2138
IDH Targeted/Non- Targeted vs Non-targeted/IDH-targeted Approaches in the Treatment of Newly Diagnosed IDH Mutated AML Patients Not Candidates for Intensive Induction Therapy (I- DATA Study)
Principal Investigator: Mat Angelos
Eligibility criteria described at link below.
COMIRB: 24-0178
Mitoxantrone for Venetoclax-Resistant Acute Myeloid Leukemia
PI: Andrew Kent
Eligibility: Ages ≥ 18; Subject must have confirmation of non-APL AML by WHO criteria and have been treated with first-line venetoclax/HMA (azacitidine or decitabine)
COMIRB: 24-2332
Phase 1b Study to Evaluate Eganelisib as Monotherapy and in Combination with Cytarabine in Patients with Relapsed/refractory Acute Myeloid Leukemia
PI: Christine McMahon
Relapsed/refractory AML; ECOG of less than or equal to 2; adequate organ function
COMIRB: 25-0718
Phase 1, Open Label, Dose Escalation Study to Evaluate the Safety, Expansion, Persistence, and Preliminary Clinical Activity of Autologous CD64 CAR T cells in Patients with Relapsed and/or Refractory Acute Myeloid Leukemia (AML)
Principal Investigator: Mat Angelos
Eligibility criteria are described in the link below.
COMIRB: 25-0787
A First-in-Human Study of the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-88549968, a T-cell Redirecting Bispecific Antibody for CALR-mutated Myeloproliferative Neoplasms
Principal Investigator: Mat Angelos
Eligibility criteria are described in the link below.
COMIRB: 25-1278
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
Principal Investigator: Christine McMahon
Eligibility criteria are described in the link below.
COMIRB: 25-2789
A Phase 1 Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti- Leukemia or anti-MDS Activity of RPT1G in Patients with Acute Myeloid Leukemia (AML) and Higher-Risk (HR) Myelodysplastic Syndromes/Neoplasms
Principal Investigator: Dan Pollyea
Eligibility criteria are described in the link below.
Request an Appointment
If you would like to schedule an appointment, please give us a call.
Our intake coordinator will help you navigate the process of becoming a new patient including helping you obtain the necessary referrals, get the necessary medical records transferred, and coordinate care with your existing physicians. We are available to answer your questions about our clinic, your treatment, and participation in ongoing clinical trials.